免疫治疗时代同步寡转移性非小细胞肺癌患者的治疗结局:真实世界意向性治疗人群分析
单中心回顾性系列纳入68例按欧洲癌症研究与治疗组织定义充分分期的同步寡转移性非小细胞肺癌患者,38例(56%)最终接受局部根治治疗。中位随访26.7个月,接受(化疗)免疫检查点抑制剂诱导者中位无进展生存期19.0个月 vs 单纯化疗6.8个月(HR 0.5,p=0.03),中位总生存期19.3个月 vs 15.7个月(HR 0.8,p=0.4)。
要点
- (化疗)免疫检查点抑制剂组中位无进展生存期19.0个月 vs 单纯化疗组6.8个月(HR 0.5,p=0.03)。
- 两组中位总生存期19.3个月 vs 15.7个月(HR 0.8,p=0.4)。
- 接受局部根治治疗者中位无进展生存期19.0个月 vs 8.3个月(HR 0.6,p=0.2)。
核心结论
- 以免疫检查点抑制剂为基础的全身治疗可行,并可能带来更优的生存结局,但需在前瞻性试验中验证。
- 同时需要改善全身治疗反应率的策略。
研究设计与样本
- 单中心回顾性系列,纳入所有按欧洲癌症研究与治疗组织定义(最多5个转移灶、累及3个器官)充分分期的同步寡转移性非小细胞肺癌患者,共68例。
- 按意向性治疗人群分析,比较接受(化疗)免疫检查点抑制剂诱导治疗与仅接受化疗(伴或不伴局部根治治疗)的患者结局。
- 主要终点为(化疗)免疫检查点抑制剂组与化疗组的中位无进展生存期和总生存期。
主要发现
- 68例患者中38例(56%)最终接受局部根治治疗。
- 中位随访26.7个月,(化疗)免疫检查点抑制剂组(n=18)中位无进展生存期19.0个月 vs 单纯化疗组(n=50)6.8个月(HR 0.5,p=0.03)。
- (化疗)免疫检查点抑制剂组中位总生存期19.3个月 vs 单纯化疗组15.7个月(HR 0.8,p=0.4)。
- 在接受局部根治治疗的患者中,(化疗)免疫检查点抑制剂组中位无进展生存期19.0个月 vs 单纯化疗组8.3个月(HR 0.6,p=0.2)。
局限性
- 本研究为单中心回顾性系列。
- 已发表的寡转移研究多数非意向性治疗分析,存在选择偏倚。
- 分期正电子发射计算机断层显像(PET-CT)和脑影像学检查常非强制,且寡转移定义异质。
- 指南推荐对全身治疗有反应的同步寡转移性非小细胞肺癌加局部根治治疗,但该推荐基于未使用免疫检查点抑制剂的研究。
- 作者指出该结果应在前瞻性试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The standard first-line treatment for non-oncogene driven metastatic non-small cell lung cancer (NSCLC) is an immune checkpoint inhibitor (ICI) based strategy. Although guidelines increasingly advise adding local radical treatment (LRT) to patients with synchronous oligometastatic (sOMD) NSCLC responding to systemic therapy, this recommendation is based on the studies without ICI. Furthermore, the majority of published oligometastatic studies were not on an intention-to-treat basis, resulting in selection bias. Moreover, staging Positron Emission Tomography-Computed Tomography (PET-CT) and brain imaging were often not mandatory and definitions of oligometastatic were heterogeneous. Therefore, this study focused on a single centre retrospective series, including all adequately staged patients with sOMD NSCLC according to the European Organisation for Research and Treatment of Cancer definition (maximum of 5 metastases in 3 organs) that were treated with induction (chemo)-ICI and compared outcomes to those treated with chemotherapy only, with and without LRT. The primary end-points were median progression-free survival (PFS) and overall survival (OS) for patients treated with induction (chemo)-ICI versus chemotherapy. Out of 68 included patients, 38 (56%) eventually received LRT. With a median follow-up of 26.7 months, the median PFS was 19.0 months for (chemo)-ICI (n = 18) versus 6.8 for chemotherapy-only (n = 50) (HR 0.5, p = 0.03), the median OS was 19.3 versus 15.7 months, respectively (HR 0.8, p = 0.4). In patients having received LRT, median PFS was 19.0 months for (chemo)-ICI versus 8.3 for chemotherapy-only (HR 0.6, p = 0.2). In conclusion, an ICI-based systemic treatment is feasible and may result in superior survival outcomes. This should be investigated in prospective trials. Strategies to improve response rates to systemic treatment are also needed.
引用
- Jongbloed M, Bartolomeo V, Steens M, et al. Treatment outcome of patients with synchronous oligometastatic non-small cell lung cancer in the immunotherapy era: Analysis of a real-life intention-to-treat population. Eur J Cancer. 2023. PMID: 37451182. doi:10.1016/j.ejca.2023.112947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。